Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome.

MLA

Lampron, Antoine, et al. “Whole Genome Expression Profiling of Glucose-Dependent Insulinotropic Peptide (GIP)- and Adrenocorticotropin-Dependent Adrenal Hyperplasias Reveals Novel Targets for the Study of GIP-Dependent Cushing’s Syndrome.” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, Sept. 2006, pp. 3611–18. EBSCOhost, https://doi.org/10.1210/jc.2006-0221.

APA

Lampron, A., Bourdeau, I., Hamet, P., Tremblay, J., & Lacroix, A. (2006). Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing’s syndrome. The Journal of Clinical Endocrinology and Metabolism, 91(9), 3611–3618. https://doi.org/10.1210/jc.2006-0221

Chicago

Lampron, Antoine, Isabelle Bourdeau, Pavel Hamet, Johanne Tremblay, and André Lacroix. 2006. “Whole Genome Expression Profiling of Glucose-Dependent Insulinotropic Peptide (GIP)- and Adrenocorticotropin-Dependent Adrenal Hyperplasias Reveals Novel Targets for the Study of GIP-Dependent Cushing’s Syndrome.” The Journal of Clinical Endocrinology and Metabolism 91 (9): 3611–18. doi:10.1210/jc.2006-0221.